Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Inclusion Criteria:

* Patients 18 years of age and ≤75 years of age
* Biopsy-proven ovarian, tubal or primary peritoneal epithelial adenocarcinomas;
* Performance status 0,1 (ECOG) ( table 2)
* Patients at high risk of clinical relapse: first remission stage III/IV who were suboptimally debulked (residual disease \>1 cm)
* Patients of any stage who have recurred and are in second chemotherapy induced remission. Clinical remission defined as:

  * absence of symptoms that may be related to disease
  * imaging without abnormalities greater then or equal to 1 cm suspicious for disease (no ascites)
  * CA 125 obtained x 1 and \<35 units/ml.
* Adequate end organ function, defined as the following:

  * Total bilirubin \< 1.5 x ULN
  * SGOT and SGPT \< 2.5 x UNL
  * Creatinine \< 1.5 x ULN
  * ANC \> 1.5 x 109/L
  * Platelets \> 100 x 109/L
  * Weight ≥ 50 kg

Exclusion Criteria:

* Patients with performance status ECOG =2,3,4
* Patients who are on warfarin or prior therapeutic anticoagulation
* Patient has another primary malignancy that has required active intervention within 5 years, with the exception of basal cell skin cancer or a cervical carcinoma in situ.
* Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
* Patient who had a major surgery within 2 weeks prior to study entry
* Patients with the following lab abnormalities:

  * WBC \<3000
  * absolute neutrophil count \< 1,500
  * hemoglobin \<10 g/dL
  * platelet \< 100,000
  * creatinine clearance \<30 cc/min
  * serum ALT, AST, or total bilirubin \>1.5X the upper limit of normal
* Patients with known bleeding disorder